$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche., Danaher, Agilent Technologies, Siemens Healthineers, and GE HealthCare

Yahoo

4 days ago

The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansion in emerging markets. This comprehensive report covers market segments, regional insights, and profiles of major players like Roche and Siemens.
Oncology Diagnostics Market
Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Oncology Diagnostics: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029.
The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period.
This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services.The oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets.
Key Attributes:
Report Attribute
Details
No. of Pages
192
Forecast Period
2024 - 2029
Estimated Market Value (USD) in 2024
$77.6 Billion
Forecasted Market Value (USD) by 2029
$101.5 Billion
Compound Annual Growth Rate
5.5%
Regions Covered
Global
The report includes:
94 data tables and 59 additional tables
Analyses of global market trends for oncology diagnostics, with market revenue data from 2021 to 2024, forecasts and projected CAGRs through 2029
Estimates of the size and growth of the global market, and a corresponding market share analysis by product type, application, end user, and region
Facts and figures pertaining to the major market dynamics, opportunities and challenges, emerging technologies, regulations, and impacts of macroeconomic variables
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Coverage of treatments in development for late- and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends
Evaluation of recent patent activity featuring key granted and published patents
Insights into oncology therapeutics research activity, emerging technologies, clinical trials and pipeline products
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Danaher Corp., Agilent Technologies Inc., Siemens Healthineers AG, and GE HealthCare
Key Topics Covered: Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Strategic Initiatives
Conclusion
Chapter 2 Market Overview
Overview
Macroeconomic Factors Analysis
Impact of the U.S.-China Trade War
Porter's Five Forces Analysis in the Oncology Market
Chapter 3 Market Dynamics
Key Takeaways
Market Drivers
Rising Incidence of Cancer Cases
Demand for Earlier Intervention and Preventive Diagnostic Screening
Growing Adoption of Companion Diagnostics
Increasing Aging Population Worldwide
Market Opportunities
Expanding Cancer Screening
Enhancing Access to Advanced Technologies
Market Restraints
Complex Reimbursement Policies
Lack of Cancer Awareness
Cost of Oncology Diagnostic Tests
Turnaround Time of Oncology Diagnostics
Market Challenges
Lack of Skilled Professionals
Complex Sample Preparation and Handling
Chapter 4 Regulatory Landscape
Market Regulations, by Top Country/Region
The U.S.
Europe
Japan
China
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
AI in Oncology Diagnostics
Multi-Cancer Early Detection (MCED)
Theranostics
Digital Pathology and AI Integration
Patent Analysis
Key Takeaways
Chapter 6 Oncology Diagnostics Market
Segment Breakdown
Global Market Insights
Market Breakdown by Product Type
Diagnostics Imaging
Endoscopy Devices
Tumor Biomarker Tests
Biopsy Devices
Hematoxylin and Eosin
Immunohistochemistry
In situ Hybridization
Polymerase Chain Reaction
Next-Generation Sequencing
Others
Market Breakdown by Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Other Applications
Market Breakdown by End User
Hospitals, Cancer Centers and Clinics
Diagnostic Imaging and Reference Laboratories
Others
Geographic Breakdown
Market Breakdown, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa (MEA)
Chapter 7 Competitive Intelligence
Company Share Analysis
Strategic Initiatives
Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective
Introduction to ESG
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks
Chapter 9 Appendix
Research Methodology
References
Abbreviations
Company Profiles
ABBOTT
AGILENT TECHNOLOGIES INC.
BD
BIOMERIEUX
BIO-RAD LABORATORIES INC.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GE HEALTHCARE
ILLUMINA INC.
KONINKLIJKE PHILIPS N.V.
MERCK KGAA
MYRIAD GENETICS INC.
QIAGEN
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
ZYTOVISION GMBH
Other Emerging Players in the Oncology Diagnostics Market
List of TablesSummary Table: Global Market for Oncology Diagnostics, by Product Type, Through 2029Table 1: Global Incidence of All Cancer Cases, by WHO Region, 2022-2045Table 2: Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022Table 3: Cancer Treatments Based on Specific TestsTable 4: Select FDA-Approved AI-Associated/Associable-Equipped Medical DevicesTable 5: Selected Patent Grants in Oncology Diagnostics, 2023-2025Table 6: Global Oncology Diagnostics Market, by Product Type, Through 2029Table 7: Global Diagnostics Imaging Market, by Region, Through 2029Table 8: Global Endoscopy Market, by Region, Through 2029Table 9: Global Tumor Biomarker Tests Market, by Region, Through 2029Table 10: Global Biopsy Devices Market, by Region, Through 2029Table 11: Global H&E and Special Stains Diagnostics Market, by Region, Through 2029Table 12: Global IHC Oncology Diagnostics Market, by Region, Through 2029Table 13: Global ISH Oncology Diagnostics Market, by Region, Through 2029Table 14: Global PCR Oncology Diagnostics Market, by Region, Through 2029Table 15: Global NGS Oncology Diagnostics Market, by Region, Through 2029Table 16: Global Other Oncology Diagnostics Tests Market, by Region, Through 2029Table 17: Global Oncology Diagnostics Market, by Application, Through 2029Table 18: Global Breast Cancer Diagnostics Market, by Region, Through 2029Table 19: Global Lung Cancer Diagnostics Market, by Region, Through 2029Table 20: Global Colorectal Cancer Diagnostics Market, by Region, Through 2029Table 21: Global Prostate Cancer Diagnostics Market, by Region, Through 2029Table 22: Global Gastric Cancer Diagnostics Market, by Region, Through 2029Table 23: Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029Table 24: Global Oncology Diagnostics Market, by End User, Through 2029Table 25: Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029Table 26: Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029Table 27: Global Oncology Diagnostics Market in Other End Uses, Through 2029Table 28: Global Oncology Diagnostics Market, by Region, Through 2029Table 29: North American Oncology Diagnostics Market, by Country, Through 2029Table 30: U.S. Oncology Diagnostics Market, by Product Type, Through 2029Table 31: U.S. Oncology Diagnostics Market, by Application, Through 2029Table 32: U.S. Oncology Diagnostics Market, by End User, Through 2029Table 33: Canadian Oncology Diagnostics Market, by Product Type, Through 2029Table 34: Canadian Oncology Diagnostics Market, by Application, Through 2029Table 35: Canadian Oncology Diagnostics Market, by End User, Through 2029Table 36: Mexican Oncology Diagnostics Market, by Product Type, Through 2029Table 37: Mexican Oncology Diagnostics Market, by Application, Through 2029Table 38: Mexican Oncology Diagnostics Market, by End User, Through 2029Table 39: European Oncology Diagnostics Market, by Country, Through 2029Table 40: Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022Table 41: German Oncology Diagnostics Market, by Product Type, Through 2029Table 42: German Oncology Diagnostics Market, by Application, Through 2029Table 43: German Oncology Diagnostics Market, by End User, Through 2029Table 44: Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022Table 45: French Oncology Diagnostics Market, by Product Type, Through 2029Table 46: French Oncology Diagnostics Market, by Application, Through 2029Table 47: French Oncology Diagnostics Market, by End User, Through 2029Table 48: New Cases of Cancer Diagnosed Each Year in the U.K., 2021Table 49: The U.K. Oncology Diagnostics Market, by Product Type, Through 2029Table 50: The U.K. Oncology Diagnostics Market, by Application, Through 2029Table 51: The U.K. Oncology Diagnostics Market, by End User, Through 2029Table 52: Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022Table 53: Italian Oncology Diagnostics Market, by Product Type, Through 2029Table 54: Italian Oncology Diagnostics Market, by Application, Through 2029Table 55: Italian Oncology Diagnostics Market, by End User, Through 2029Table 56: Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022Table 57: Spanish Oncology Diagnostics Market, by Product Type, Through 2029Table 58: Spanish Oncology Diagnostics Market, by Application, Through 2029Table 59: Spanish Oncology Diagnostics Market, by End User, Through 2029Table 60: Rest of European Countries' Oncology Diagnostics Market, by Product Type, Through 2029Table 61: Rest of European Countries' Oncology Diagnostics Market, by Application, Through 2029Table 62: Rest of European Countries' Oncology Diagnostics Market, by End User, Through 2029Table 63: Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029Table 64: Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022Table 65: Chinese Oncology Diagnostics Market, by Product Type, Through 2029Table 66: Chinese Oncology Diagnostics Market, by Application, Through 2029Table 67: Chinese Oncology Diagnostics Market, by End User, Through 2029Table 68: Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022Table 69: Japanese Oncology Diagnostics Market, by Product Type, Through 2029Table 70: Japanese Oncology Diagnostics Market, by Application, Through 2029Table 71: Japanese Oncology Diagnostics Market, by End User, Through 2029Table 72: Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022Table 73: Indian Oncology Diagnostics Market, by Product Type, Through 2029Table 74: Indian Oncology Diagnostics Market, by Application, Through 2029Table 75: Indian Oncology Diagnostics Market, by End User, Through 2029Table 76: Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029Table 77: Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029Table 78: Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029Table 79: South American Oncology Diagnostics Market, by Country, Through 2029Table 80: Brazilian Oncology Diagnostics Market, by Product Type, Through 2029Table 81: Brazilian Oncology Diagnostics Market, by Application, Through 2029Table 82: Brazilian Oncology Diagnostics Market, by End User, Through 2029Table 83: Argentine Oncology Diagnostics Market, by Product Type, Through 2029Table 84: Argentine Oncology Diagnostics Market, by Application, Through 2029Table 85: Argentine Oncology Diagnostics Market, by End User, Through 2029Table 86: Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029Table 87: Rest of South American Oncology Diagnostics Market, by Application, Through 2029Table 88: Rest of South American Oncology Diagnostics Market, by End User, Through 2029Table 89: Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029Table 90: Middle East and African Oncology Diagnostics Market, by Application, Through 2029Table 91: Middle East and African Oncology Diagnostics Market, by End User, Through 2029Table 92: Company Shares in the Oncology Diagnostics Market, 2023Table 93: ESG: Environmental OverviewTable 94: ESG: Social OverviewTable 95: ESG: Governance OverviewTable 96: Abbreviations Used in this ReportTable 97: Abbott: Company SnapshotTable 98: Abbott: Financial Performance, FY 2022 and 2023Table 99: Abbott: Product PortfolioTable 100: Agilent Technologies Inc.: Company SnapshotTable 101: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024Table 102: Agilent Technologies Inc.: Product PortfolioTable 103: Agilent Technologies Inc.: News/Key Developments, 2024Table 104: BD: Company SnapshotTable 105: BD: Financial Performance, FY 2023 and 2024Table 106: BD: Product PortfolioTable 107: bioMerieux: Company SnapshotTable 108: bioMerieux: Financial Performance, FY 2022 and 2023Table 109: bioMerieux: Product PortfolioTable 110: Bio-Rad Laboratories Inc.: Company SnapshotTable 111: Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024Table 112: Bio-Rad Laboratories Inc.: Product PortfolioTable 113: Danaher Corp.: Company SnapshotTable 114: Danaher Corp.: Financial Performance, FY 2022 and 2023Table 115: Danaher Corp.: Product PortfolioTable 116: Danaher Corp.: News/Key Developments, 2023Table 117: F. Hoffmann-La Roche Ltd.: Company SnapshotTable 118: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024Table 119: F. Hoffmann-La Roche Ltd.: Product PortfolioTable 120: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025Table 121: GE HealthCare: Company SnapshotTable 122: GE HealthCare: Financial Performance, FY 2023 and 2024Table 123: GE HealthCare: Product PortfolioTable 124: GE HealthCare: News/Key Developments, 2024Table 125: Illumina Inc.: Company SnapshotTable 126: Illumina Inc.: Financial Performance, FY 2023 and 2024Table 127: Illumina Inc.: Product PortfolioTable 128: Illumina Inc.: News/Key Developments, 2024Table 129: Koninklijke Philips N.V.: Company SnapshotTable 130: Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024Table 131: Koninklijke Philips N.V.: Product PortfolioTable 132: Merck KGaA: Company SnapshotTable 133: Merck KGaA: Financial Performance, FY 2022 and 2023Table 134: Merck KGaA: Product PortfolioTable 135: Myriad Genetics Inc.: Company SnapshotTable 136: Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023Table 137: Myriad Genetics Inc.: Product PortfolioTable 138: Myriad Genetics Inc.: News/Key Developments, 2025Table 139: Qiagen: Company SnapshotTable 140: Qiagen: Financial Performance, FY 2022 and 2023Table 141: Qiagen: Product PortfolioTable 142: Siemens Healthineers AG: Company SnapshotTable 143: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024Table 144: Siemens Healthineers AG: Product PortfolioTable 145: Siemens Healthineers AG: News/Key Developments, 2024Table 146: Thermo Fisher Scientific Inc.: Company SnapshotTable 147: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023Table 148: Thermo Fisher Scientific Inc.: Product PortfolioTable 149: Thermo Fisher Scientific Inc.: News/Key Developments, 2023Table 150: ZytoVision GmbH: Company SnapshotTable 151: ZytoVision GmbH: Product PortfolioTable 152: Emerging Startups in Oncology Diagnostics MarketList of FiguresSummary Figure: Global Market Shares of Oncology Diagnostics, by Product Type, 2023Figure 1: Porter's Five Forces Analysis of the Oncology MarketFigure 2: Market Dynamics of Oncology DiagnosticsFigure 3: Global Incidence Shares of All Cancer Cases, by Region, 2022Figure 4: Number of FDA-Approved Companion Diagnostic Devices, 1997-2024Figure 5: Emerging Trends and Technologies in Oncology DiagnosticsFigure 6: Share of Global Market for Oncology Diagnostics, by Product Type, 2023Figure 7: Share of Global Market for Oncology Diagnostics, by Application, 2023Figure 8: Shares of Global Market for Oncology Diagnostics, by End User, 2023Figure 9: Share of Global Market for Oncology Diagnostics, by Region, 2023Figure 10: Share of North American Market for Oncology Diagnostics, by Country, 2023Figure 11: Share of European Market for Oncology Diagnostics, by Country, 2023Figure 12: Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022Figure 13: Cervical Cancer Screening Rates in European Countries, 2022Figure 14: Colorectal Cancer Screening Rates in European Countries, 2022Figure 15: Current and Forecasted Cancer Prevalence in the U.K., 2020-2040Figure 16: Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022Figure 17: Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022Figure 18: Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023Figure 19: Share of South American Market for Oncology Diagnostics, by Country, 2023Figure 20: Share of the Global Market for Oncology Diagnostics, by Company, 2023Figure 21: ESG PillarsFigure 22: Advantages of ESG for CompaniesFigure 23: Abbott: Revenue Share, by Business Unit, FY 2023Figure 24: Abbott: Revenue Share, by Country/Region, FY 2023Figure 25: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024Figure 26: Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024Figure 27: BD: Revenue Share, by Business Unit, FY 2024Figure 28: BD: Revenue Share, by Country/Region, FY 2024Figure 29: bioMerieux: Revenue Share, by Business Unit, FY 2023Figure 30: bioMerieux: Revenue Share, by Region, FY 2023Figure 31: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024Figure 32: Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024Figure 33: Danaher Corp.: Revenue Share, by Business Unit, FY 2023Figure 34: Danaher Corp.: Revenue Share, by Country/Region, FY 2023Figure 35: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024Figure 36: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024Figure 37: GE HealthCare: Revenue Share, by Business Unit, FY 2024Figure 38: GE HealthCare: Revenue Share, by Country/Region, FY 2024Figure 39: Illumina Inc.: Revenue Share, by Business Unit, FY 2024Figure 40: Illumina Inc.: Revenue Share, by Country/Region, FY 2024Figure 41: Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024Figure 42: Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023Figure 43: Merck KGaA: Market Share, by Business Unit, 2023Figure 44: Merck KGaA: Revenue Share, by Country/Region, 2023Figure 45: Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023Figure 46: Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023Figure 47: Qiagen: Revenue Share, by Business Unit, FY 2023Figure 48: Qiagen: Revenue Share, by Country/Region, FY 2023Figure 49: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024Figure 50: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024Figure 51: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023Figure 52: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023Companies Featured
Abbott
Agilent Technologies Inc.
BD
bioMerieux
Bio-Rad Laboratories Inc.
Danaher Corp.
F. Hoffmann-La Roche Ltd.
GE Healthcare
Illumina Inc.
Koninklijke Philips N.V.
Merck KGaA
Myriad Genetics Inc.
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
ZytoVision GmbH
For more information about this report visit https://www.researchandmarkets.com/r/80hrjw
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Oncology Diagnostics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [e-mail] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call [phone]